NJ-BEIGENE

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the opening of its flagship U.S. facility in Hopewell, N.J., at the Princeton West Innovation Campus, which houses state-of-the-art biologics manufacturing capabilities and a clinical research and development center that further bolster the Company’s differentiated model as an oncology innovator. BeiGene has more than 30 molecules at clinical or commercial stage, and the 42-acre facility provides flexibility to scale production of its innovative medicines today and in the future to meet the needs of patients with cancer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240723282527/en/

“BeiGene has experienced unprecedented global growth, and the addition of our facility at the Princeton West Innovation Campus adds manufacturing and clinical development capabilities that will further strengthen our differentiated strategy which leverages speed, efficiency and technology to advance quality medicines faster for patients,” said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene. “We are proud to be a part of New Jersey’s biopharmaceutical community that is rich in research and development and manufacturing talent. We look forward to deepening our relationships with key regional research institutions as we advance our robust pipeline of next-generation hematology and solid tumor medicines and continue to emerge as a leading global oncology innovator.”

BeiGene’s $800 million investment is the culmination of a three-year project to expand the Company’s integrated manufacturing and research and development footprint in the U.S. BeiGene will create hundreds of skilled high-tech jobs at the site by the end of 2025. New Jersey is a global leader in biopharmaceutical manufacturing and R&D with nine of the top 10 R&D companies in the world having a presence in the state. New Jersey boasts one of the country’s leading biopharmaceutical manufacturing workforces, and its infrastructure and connectivity ensure access to major markets around the world.

“I am thrilled by BeiGene’s contribution to our state’s thriving biopharmaceutical sector,” said Governor Phil Murphy. “The opening of BeiGene’s flagship campus underscores our commitment to fostering innovation and creating high-tech jobs in the Garden State. We look forward to the positive impact BeiGene will have on our economy and the advancements they will bring to cancer treatment. This significant investment highlights New Jersey’s role as a global leader in pharmaceutical manufacturing, research and development. We are proud to support BeiGene’s mission to develop affordable and accessible treatments for cancer patients worldwide.”

The site features approximately 400,000 square feet of dedicated commercial-stage biologic pharmaceutical manufacturing capacity with space to expand over time, allowing flexibility as BeiGene’s pipeline continues to mature. The facility adds to BeiGene’s late-stage research and clinical development capabilities, which have enabled the Company’s fast rise to global oncology leadership. BeiGene has built one of the industry’s deepest and most compelling oncology pipelines, addressing 80 percent of the world’s cancers with innovative modalities such as targeted degraders and antibody drug conjugates (ADCs), in addition to monoclonal antibodies and traditional small molecules. The new facility builds on BeiGene’s existing capabilities, enabling the Company to produce at scale, thereby reducing costs, ensuring supply chain resiliency, avoiding global disruptions, protecting capacity and rapidly adapting to the latest innovative modalities.

“I am excited to welcome BeiGene to Hopewell Township. BeiGene’s new cutting-edge pharmaceutical facility represents a significant investment in our community’s future. The life-saving medicines made right here in Hopewell will not only enhance global cancer treatment, but will also create good-paying, high-tech jobs and strengthen our local economy,” said Hopewell Township Mayor Courtney Peters-Manning. “We look forward to the company’s continued success in Hopewell Township.”

BeiGene recognizes that human health and the health of the planet are intrinsically linked, and the Company is committed to reducing our environmental impact. For this reason, the Company has invested in sustainability measures both in the buildings and surrounding 42 acres, including a heating and cooling system that uses recycled wastewater from the onsite wastewater treatment plant for the cooling towers. The site also is solar-ready in line with our longer-term sustainability plan. More details on the facility, including multimedia assets, are available online at: https://www.beigene.com/hopewell.

About BeiGene

BeiGene is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter), Facebook and Instagram.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the ability of the Hopewell facility to expand and scale the Company’s strength around the world; BeiGene’s ability to deepen relationships with key regional research institutions; and BeiGene’s plans, commitments, aspirations, and goals under the heading “About BeiGene.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeiGene’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240723282527/en/